SENP1启动子G-四链体鉴定及其作用研究

目的:研究G-四链体(G4)对SUMO特异性蛋白酶1(SUMO-specific proteases 1,SENP1)基因的转录调控作用。方法:克隆不同的SENP1启动子片段构建SENP1启动子报告质粒,通过报告基因检测鉴定SENP1启动子核心转录调控区;分析SENP1启动子核心转录调控区序列,并进行G4形成序列预测;合成G4形成序列寡核苷酸,利用圆二色谱分析检测G4形成序列寡核苷酸的拓扑结构;通过G4配体TMPyP4处理和过表达G4解旋酶G4R1结合报告基因检测和Western blot鉴定启动子G4对SENP1转录表达的调控作用。结果:发现-910～+226区域是SENP1启动子的核心转录调控区,序列富含G/C;生信分析发现SENP1启动子核心区存在G4形成序列;圆二色谱分析证实SENP1启动子G4形成序列能够形成G4结构;报告基因检测和Western blot检测发现启动子G4对SENP1转录表达具有抑制作用。结论:SENP1启动子核心转录调控区存在G4结构并对其转录表达具有抑制作用,为揭示SENP1在生理和病理过程中的作用机制提供新的研究思路和试验线索。     

SENP1启动子G-四链体鉴定及其作用研究 *

目的:研究G-四链体(G4)对SUMO特异性蛋白酶1(SUMO-specific proteases 1, SENP1)基因的转录调控作用。方法:克隆不同的SENP1启动子片段构建SENP1启动子报告质粒,通过报告基因检测鉴定SENP1启动子核心转录调控区;分析SENP1启动子核心转录调控区序列,并进行G4形成序列预测;合成G4形成序列寡核苷酸,利用圆二色谱分析检测G4形成序列寡核苷酸的拓扑结构;通过G4配体TMPyP4处理和过表达G4解旋酶G4R1结合报告基因检测和Western blot鉴定启动子G4对 SENP1转录表达的调控作用。结果:发现-910 ~+226区域是SENP1启动子的核心转录调控区,序列富含G/C;生信分析发现SENP1启动子核心区存在G4形成序列;圆二色谱分析证实SENP1启动子G4形成序列能够形成G4结构;报告基因检测和Western blot检测发现启动子G4对SENP1转录表达具有抑制作用。结论:SENP1启动子核心转录调控区存在G4结构并对其转录表达具有抑制作用,为揭示SENP1在生理和病理过程中的作用机制提供新的研究思路和试验线索。     

Kruppel样因子4对内毒素所致IL-6基因表达的调控及机制研究

探讨Kruppel样因子4(KLF4)对内毒素所致白介素(IL-6)的基因表达以及释放的影响,并对其调控机制做了初步研究．使用RT-PCR和Western blot检测KLF4 mRNA和蛋白质的表达．采用KLF4过表达的RAW264.7巨噬细胞株或反义寡核苷酸技术抑制内源性KLF4的表达,用RT-PCR和ELISA检测内毒素(LPS)刺激后IL-6 mRNA和蛋白质的表达．采用荧光素酶报告基因检测RAW264.7细胞中KLF4过表达对IL-6基因启动子报告基因转录活性的影响．使用EMSA法检测细胞中KLF4与IL-6基因启动子区KLF4元件的结合．结果表明：LPS可以诱导RAW264.7巨噬细胞KLF4的表达以及IL-6蛋白表达．KLF4过表达明显抑制IL-6的mRNA和蛋白质的表达,而KLF4缺失使这种作用消失．荧光素酶报告基因的结果显示,KLF4可以抑制LPS所致的IL-6基因启动子的转录活性．EMSA显示KLF4不能与IL-6启动子区的KLF4结合元件直接结合．结果表明,LPS可以促进RAW264.7小鼠巨噬细胞KLF4的表达和IL-6的释放．KLF4能抑制LPS诱导的IL-6表达和释放,其机制是抑制IL-6启动子的转录活性,但KLF4的抑制作用不是通过直接与IL-6基因的启动子区相结合而实现的．     

大肠杆菌yigP基因转录调控序列的鉴定

【目的】调查yigP基因启动子的活性,并对该转录调控序列进行分析。【方法】以lacZ为报告基因,克隆启动子片段至启动子探针质粒中,通过检测β-半乳糖苷酶活性判断启动子活性,并通过克隆一系列逐步缩短的启动子片段来确定启动子所在区域。利用定点突变技术,对启动子的重要序列进行定点突变,调查其对启动子活性的影响。【结果】确定了yigP基因启动子的区域,鉴定了启动子的-10区和-35区,并发现了启动子上游存在一个负调控序列,对该序列进行了初步的研究显示其中部分序列是这种负调控作用的核心序列。【结论】对yigP基因的转录调控序列进行了鉴定,丰富了我们对基因转录调控的认识。     

H-NS蛋白对副溶血弧菌hcp1的转录调控

【目的】研究调控子H-NS对副溶血弧菌T6SS1结构蛋白基因hcp1的转录调控机制。【方法】利用Western blot检测Hcp1蛋白在野生株(WT)和hns基因敲除株(Δhns)中表达水平的差异。提取WT和Δhns的总RNA,采用实时定量RT-PCR的方法验证H-NS对hcp1的转录调控关系。进而采用引物延伸实验研究hcp1的转录起始位点,并根据产物的丰度判断H-NS对hcp1的调控关系。PCR扩增hcp1的整个启动子区DNA序列,并纯化His-H-NS蛋白,通过凝胶阻滞实验(EMSA)验证His-H-NS对hcp1启动子区是否具有直接的结合作用。【结果】Western blot和实时定量RT-PCR结果显示H-NS能抑制hcp1的表达;引物延伸结果显示hcp1只有一个转录起始位点T(–62)(翻译起始位点为+1),且其转录活性是H-NS和σ54依赖性的;EMSA实验表明H-NS对hcp1的启动子区具有直接的结合作用。【结论】H-NS能直接结合到hcp1启动子区而抑制其转录表达。     

几种肿瘤细胞中ezrin基因增强子区转录调控特性的研究

该文采用Western blot技术检测人食管癌EC109细胞、鼻咽癌CNE2细胞和宫颈癌HeLa细胞Ezrin蛋白的表达：采用DNA片段定向克隆技术构建一系列携带ezrin基因增强子区-1541／-706序列的报告基因表达载体,将载体瞬时转染EC109、CNE2和HeLa细胞,检测荧光素酶活性;研究肿瘤细胞中ezrin基因增强子区的转录调控特性。实验结果显示,在被检测的三种肿瘤细胞中,Ezfin蛋白的表达水平没有明显不同。Ec109细胞中,当ezrin基因-1541／-706N段正向位于无启动子的报告基因上游时,表现出类似启动子的转录激活作用：当这一片段反向连接时转录激活作用几乎消失。当-1541／-706片段正向位于ezrin启动子或SV40启动子上游时,显著增强荧光素酶表达;然而,当这一片段反向位于启动子上游以及正向或反向位于启动子控制的报告基因下游时,转录增强作用消失。ezrin基因-1541／-706N段在CNE2和HeLa细胞中的转录调控作用,与其在EC109细胞中的转录调控作用部分相似,但不完全相同。结果表明,ezrin基因增强子区具有转录激活和转录增强双重作用,这种作用具有DNA序列位置和方向依赖性以及细胞特异性。     

PD-1核心启动子的获得及活性鉴定

目的:构建PD-1(programmed death receptor 1)全长启动子及不同截短体的报告基因,并对其转录活性进行检测。方法:通过PCR及双酶切方法,从人全血基因组DNA中获得PD-1基因编码序列,包含不同长度碱基的PD-1启动子序列,分别克隆到报告基因pGL3-Basic载体上,构建8个不同长度PD-1启动子的报告基因;用脂质体转染法将8个报告基因分别转染至Jurkat细胞系;采用双萤光素酶报告基因系统评估PD-1启动子的活性。结果:经PCR方法扩增出大小分别为1650、1450、1250、1128、874、674、474和274 bp的不同长度的PD-1启动子序列,测序正确(与GenBank报道一致),酶切鉴定正确;瞬时转染Jurkat细胞系后经报告基因检测,8个启动子均具有转录活性。结论:构建了PD-1启动子的报告基因,并证实均有转录活性,且以pGL3-1128活性最高,为PD-1的核心启动子,为进一步研究PD-1的转录调控奠定了实验基础。     

p53过表达抑制同源盒基因NKX3.1启动子活性

NKX3.1是前列腺特异表达的同源盒基因,在前列腺癌的发生发展中起重要作用,而在前列腺癌进展中常会发生p53的基因突变.为研究两者之间的关系,构建NKX-3.1启动子(1 040bp)-荧光素酶报告基因重组质粒（pGL3-1040）及其缺失突变体,瞬时转染前列腺癌细胞LNCaP.通过荧光素酶表达活性分析,检测p53过表达对NKX3.1启动子活性的影响.结果表明：p53在LNCaP细胞中过表达可明显抑制NKX3.1启动子活性;RT-PCR及Western印迹检测p53过表达对NKX3.1表达的影响.结果表明,p53过表达可以明显抑制同源盒基因NKX3.1的表达.通过TRANSFAC软件分析,在NKX3.1基因上游-526至-507区存在一个p53反应元件的5′核心序列.缺失pGL3-1040中的p53反应元件核心序列并不能消除p53对NKX3.1启动子的抑制作用,表明p53不是通过p53反应元件直接抑制NKX3.1启动子活性.进一步通过5′缺失突变分析,发现NKX3.1启动子-140～+8 bp区仍受p53负调控.此148 bp区域中含有一个Sp1和一个CREB元件,瞬时共转染Sp1表达载体或CREB表达载体的结果表明,p53并不是通过与Sp1或CREB相互作用对NKX3.1启动子发挥抑制作用的.上述结果表明,p53过表达可以抑制同源盒基因NKX3.1启动子活性,下调NKX3.1基因的转录,其调控机制有待进一步研究.     

HPD基因启动子报告基因载体构建与转录活性分析

目的:HPD是一种酪氨酸分解代谢途径中的关键酶,特异表达于肝脏。目前对HPD的研究主要集中在HPD与酪氨酸血症等疾病的关系上,而对其转录调控的报道较少,并且对HPD在肝脏中特异性表达的转录调控机制尚不清楚,也未见报道。通过构建HPD基因启动子荧光素酶报告基因载体,检测其在肝源细胞中的特异转录活性,进而揭示其肝脏特异性表达的调控机制。方法:运用UCSC在线数据库分析人HPD基因组结构,并获得其5'端上游启动子区域-2000~+39bp的DNA序列。以人的肝癌细胞Hep G2基因组DNA为模板,利用PCR扩增该序列,并克隆到p GL3-Basic荧光素酶报告基因载体上。通过设计不同引物,进一步构建系列缺失体,共获得7个不同长度的荧光素酶报告基因载体。将构建的载体分别转染Hep G2、L02及HEK293细胞,通过双荧光素酶活性分析实验检测不同缺失体的转录活性。结果:报告基因实验结果显示-600~-400区域在肝源细胞系Hep G2和L02细胞中具有较强转录活性,而在HEK293细胞中活性较低,-400~+39区段则在两种细胞中均有转录活性。生物信息学分析结果显示-600~-400区域内存在较多肝脏特异性转录因子结合位点。结论:成功构建了HPD基因启动子荧光素酶报告基因载体,发现-600~-400存在调控HPD肝脏特异表达的关键元件,为进一步深入揭示HPD肝脏特异性表达的转录调控机制奠定了理论基础。     

Some novel flavin-nicotinamide biscoenzymes and their reactivities

The present study was undertaken to investigate flavin-nicotinamide reactions and interactions. A series of novel flavin-nicotinamide biscoenzymes have been synthesized by a general three-step procedure. The structures of these compounds were confirmed by nuclear magnetic resonance spectra, absorption spectra and elemental analysis. These compounds consist of short linear hydrocarbon chains interconnecting the N-1 of nicotinamide and the N-10 of the 7,8-dimethyl-isoalloxazine ring. The compounds were reduced with sodium dithionite (Na₂S₂O₄) and the flavin portion was reoxidized with ferricyanide. Re-reduction of the flavin portion by the nicotinamide portion of the molecule was followed anaerobically at 442 nm. When the interconnecting hydrocarbon chain was unsaturated, a second order reaction was observed with a rate equal to that of lumiflavin and 1-propyl-1,4-dihydronicotinamide (NprNicH₂) under the same conditions. When the two halves of the biscoenzymes were connected by saturated three- and four-carbon chains, the expected unimolecular reaction was not observed. Instead, the reduced biscoenzyme, after separation from excess sodium dithionite, was shown to have a strong absorption at 298 nm. This absorption is characteristic of hydration of dihydronicotinamides at the 5,6-double bond.In further studies, the C₃-biscoenzyme exhibited an absorption at 600 nm due to a complex between the reduced flavin and oxidized nicotinamide portions of the molecule. Absorbance at 600 nm increased linearly with the C₃-biscoenzyme concentration, clearly indicating that this is an intramolecular complex. When the C₃-biscoenzyme was at 0°C in 60–75% dimethylformamide buffer solution, no absorption at 600 nm was observed. When excess dithionite was removed, the spectrum under these conditions showed definite peaks at 297 and 357 nm. These respective peaks were attributed to hydrated dihydronicotinamide and dihydronicotinamide species present in the reaction mixture.The reduced flavin was postulated to be a catalyst for the hydration of dihydronicotinamide. This hypothesis was tested by incubating 1-propyl-1,4-dihydronicotinamide alone and with several concentrations of reduced riboflavin under basic anaerobic conditions. The results show that the reduced flavin increases the rate of disappearance of the dihydronicotinamide species and that the product shows an absorption near 298 nm. These results indicate that a reduced form of the flavin nucleus catalyzes the hydration of dihydronicotinamides.     

Identification of 4-acetoxyaminoquinoline from the hydrolysis of 1-acetoxy-4-acetoxyimino-1,4-dihydroquinoline,in vitro and in vivo properties

4-Acetoxyaminoquinoline (Ac-4-HAQ) (1) was identified as a hydrolysis product of 1-acetoxy-4-acetoxyimino-1,4-dihydroquinoline (diAc-4-HAQO). The reaction allowing the obtention of (1) obeys to a reduction mechanism implying the N₁-O cleavage. The carcinogenic properties of (1) observed by Sato et al. (Japan J. Exp. Med., 40 (1970) 475) in mice were studied in rats with the in vivo system we used previously with 4-nitroquinoline-1-oxide (4-NQO) and 4-hydroxyaminoquinoline-1-oxide (4-HAQO). In rats (1) does not covalently bind DNA. It was, therefore, possible to propose an interpretation of the results obtained by Enomoto et al. (Proc. Soc. Exp. Biol. Med., 136 (1971) 1206) who injected diAc-4-HAQO s.c. to mice and rats. Compound 1 could be responsible for the carcinogenic effects observed through the following pathway: (1) should be formed by hydrolysis of diAc-4-HAQO and reactivated by an enzymatic system to N-oxide derivative, the 4-acetoxyaminoquinoline-1-oxide (Ac-4-HAQO), which constitutes an ultimate carcinogen model of 4-NQO.     

The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206

Cap-dependent translation is a potential cancer-related target (oncotarget) due to its critical role in cancer initiation and progression. 4EGI-1, an inhibitor of eIF4E/eIF4G interaction, was discovered by screening chemical libraries of small molecules. 4EGI-1 inhibits cap-dependent translation initiation by impairing the assembly of the eIF4E/eIF4G complex, and therefore is a potential anti-cancer agent. Here, we report that 4EGI-1 also inhibits mTORC1 signaling independent of its inhibitory role on cap-dependent translation initiation. The inhibition of mTORC1 signaling by 4EGI-1 activates Akt due to both abrogation of the negative feedback loops from mTORC1 to PI3K and activation of mTORC2. We further validated that mTORC2 activity is required for 4EGI-1-mediated Akt activation. The activated Akt counteracted the anticancer effects of 4EGI-1. In support of this model, inhibition of Akt potentiates the antitumor activity of 4EGI-1 both in vitro and in a xenograft mouse model in vivo. Our results suggest that a combination of 4EGI-1and Akt inhibitor is a rational approach for the treatment of cancer.     

The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206

Cap-dependent translation is a potential cancer-related target (oncotarget) due to its critical role in cancer initiation and progression. 4EGI-1, an inhibitor of eIF4E/eIF4G interaction, was discovered by screening chemical libraries of small molecules. 4EGI-1 inhibits cap-dependent translation initiation by impairing the assembly of the eIF4E/eIF4G complex, and therefore is a potential anti-cancer agent. Here, we report that 4EGI-1 also inhibits mTORC1 signaling independent of its inhibitory role on cap-dependent translation initiation. The inhibition of mTORC1 signaling by 4EGI-1 activates Akt due to both abrogation of the negative feedback loops from mTORC1 to PI3K and activation of mTORC2. We further validated that mTORC2 activity is required for 4EGI-1-mediated Akt activation. The activated Akt counteracted the anticancer effects of 4EGI-1. In support of this model, inhibition of Akt potentiates the antitumor activity of 4EGI-1 both in vitro and in a xenograft mouse model in vivo. Our results suggest that a combination of 4EGI-1and Akt inhibitor is a rational approach for the treatment of cancer.     

Quinone-enhanced ascorbate reduction of nitric oxide: role of quinone redox potential

The quinones 1,4-naphthoquinone (NQ), methyl-1,4-naphthoquinone (MNQ), trimethyl-1,4-benzoquinone (TMQ) and 2,3-dimethoxy-5-methyl-1,4-benzoquinone (UQ-0) enhance the rate of nitric oxide (NO) reduction by ascorbate in nitrogen-saturated phosphate buffer (pH 7.4). The observed rate constants for this reaction were determined to be 16±2,215±6,290±14 and 462±18 M^-1 s^-1, for MNQ, TMQ, NQ and UQ-0, respectively. These rate constants increase with an increase in quinone one-electron redox potential at neutral pH, E₇¹. Since NO production is enhanced under hypoxia and under certain pathological conditions, the observations obtained in this work are very relevant to such conditions.     

Crystal Structure of Human Myosin 1c—The Motor in GLUT4 Exocytosis: Implications for Ca Regulation and 14-3-3 Binding

Myosin 1c (Myo1c) plays a key role in supporting motile events that underlie cell migration, vesicle trafficking, insulin-stimulated glucose uptake and hearing. Here, we present the crystal structure of the human Myo1c motor in complex with its light chain calmodulin. Our structure reveals tight interactions of the motor domain with calmodulin bound to the first IQ motif in the neck region. Several of the calmodulin residues contributing to this interaction are also involved in Ca^2 + binding. Contact residues in the motor domain are linked to the central β-sheet and the HO helix, suggesting a mechanism for communicating changes in Ca^2 + binding in the neck region to the actin and nucleotide binding regions of the motor domain. The structural context and the chemical environment of Myo1c mutations that are involved in sensorineural hearing loss in humans are described and their impact on motor function is discussed. We show that a construct consisting of the motor domain of Myo1c and the first IQ motif is sufficient to establish a tight interaction with 14-3-3β (K_D = 0.9 μM) and present the model of a double-headed Myo1c–14-3-3 complex. This complex has been implicated in the exocytosis of glucose transporter 4 storage vesicles during insulin-stimulated glucose uptake.     

4E-BP1、4E-BP1-4A 重组慢病毒载体的构建及对胃癌细胞 HGC27生长的影响

目的:构建4E-BP1及其 T37A、T46A、S65A、T70A 突变体4E-BP1-4A 基表达的重组慢病毒载体,研究其对胃癌 HGC27细胞生长的影响.方法:PCR 扩增4E-BP1基及其突变体4E-BP1-4A 基并克隆到 pCDH 载体,构建成 pCDH-4E-BP1、pCDH-4E-BP1-4A,将其与包装载体共转染293T 细胞,包装成 Lenti-4E-BP1及 Lenti-4E-BP1-4A重组慢病毒载体,将此慢病毒感染胃癌 HGC27细胞,Western 印迹鉴定病毒载体介导的4E-BP1、4E-BP1-4A 蛋白的表达,MTT、克隆形成和软琼脂方法研究过量表达4E-BP1、4E-BP1-4A 对胃癌 HGC27细胞生长的影响.结果:包装成 Lenti-4E-BP1及 Lenti-4E-BP1-4A 重组慢病毒载体,并将此慢病毒载体感染胃癌 HGC27细胞;MTT、克隆形成、软琼脂实验表明过量表达4E-BP1可抑制胃癌 HGC27细胞的生长,过量表达4E-BP1-4A 时抑制效果更明显.结论:构建了4E-BP1、4E-BP1-4A 的重组慢病毒表达载体,在胃癌 HGC27细胞中过量表达4E-BP1可抑制细胞生长,过量表达4E-BP1-4A 的抑制效果更明显.